drugset / Trial / NCT03484611

Prediction of Metaphase II Oocytes According to Different Levels of Serum AMH in Poor Responders Using the Antagonist Protocol

NCT03484611

Unknown 179 enrolled Cairo University
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

A multicentric study looked into 179 poor responders who underwent antagonist protocol in ICSI cycles Gonadotrophines is started on day 2 with HMG until the day of HCG administration with starting dose 300IU to 450IU,with no pretreatment with OCPs or progestogens or estrogen. GNRH antagonist (cetrorelix 0,25mg s.c, cetrotide, serono laboratories, Aubonne Switzerland) is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration Ovarian ultrasound scans were performed using a 5.0-9.0 MHZ multi frequency trans vaginal probe to assess the ovarian response till the mature follicles reach18-20mm when hCG administration 10000 IU is given to induce final oocytes maturation , serum E2 is done on day of HCG trigger. Trans vaginal ultrasound-guided oocyte retrieval is performed 34-36 hours after hCG injection. Ultrasound -guided fresh embryo transfer is performed on day 3 or 5 after fertilization. Progesterone support of luteal phase was commenced on the day of ovum pick up using prontogest 400 mg twice daily.

Timeline

Start
2013-01
Primary completion
2018-04
Completion
2018-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cetrorelix Other / unclassified 0.25 mg Subcutaneous
Comparator Progesterone Other / unclassified 400 mg Other
Comparator human chorionic gonadotropin Protein / enzyme biologic 300 iu
Comparator human chorionic gonadotropin Protein / enzyme biologic 450 iu
Comparator human chorionic gonadotropin Protein / enzyme biologic 10000 iu

Indications

No indication recorded.